A synergistic antimicrobial composition for use in personal care products functions as an antifungal agent in hair shampoo and hair care products, and includes (A) an undecylenic acid based phosphobetaine depicted by Formula I, where R=Undecylenic acid: ##STR00001##
and (B) a sophorolipid, a biosurfactant produced by a fermentation process using Candida bombicola, having a structure as depicted by Formula II(A), Formula II(B), or a mixture thereof: ##STR00002##

A hydrogen-containing composition for ingestion or topical use and method of producing the hydrogen-containing composition are provided. The composition includes a carrier liquid and molecular hydrogen. The concentration of molecular hydrogen in the carrier liquid is greater than 3 ppm.

A method of treating atopic dermatitis and/or psoriasis comprising the application of select dilinoleate isohexides to the skin.

Oral care compositions with an anticaries or anticavity effect. Oral care compositions that are have an extract from a species in the Humulus family and an anticaries drug, such as a fluoride ion source. Oral care compositions have fluoride and hops beta acid, such as from an extract from Humulus lupulus. Oral care compositions have a fluoride ion source and a hops beta acid derived from an extract of Humulus lupulus.

A personal cleansing composition includes from about 1% to about 15% of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth(n) sulfate (SLEnS), wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3; from about 0.01% to about 1% of an organic acid having a pKa greater than about 2.7, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and wherein the pH of the personal cleansing composition is from about 5.0 to about 6.5.

The inventive subject is directed towards ready-to-use topical cosmetic formulations that include at least one defensin present in sub-antimicrobially effective concentrations. Surprisingly, even at such low concentrations, defensins recruit LGR6+ stem cells from hair follicles to the interfollicular space. Including defensins in the inventive topical cosmetic formulations may reduce one or more of wrinkle depth, wrinkle length, wrinkle width, pore size, irregularity in texture of a skin surface, oiliness, brown spots, and red spots in non-injured skin, thus reducing apparent age.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tis -sue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

A medical device or solution for treating dental discomfort by at least partially occluding dental tubules is disclosed. The medical device or solution contains a polysaccharide or other biocompatible polymer with an antimicrobial metal, antimicrobial metal compound, or antimicrobial metal ion bound to a biopolymer. The medical device or solution further comprises at least one soluble antimicrobial. The soluble antimicrobial may be a water soluble metal iodide, water soluble metal fluoride, or a water soluble metal chloride encompassed with the nanogel. The medical device may be a solution of a chitosan with a nanoparticle of silver fluoride on the chitosan and at least one of a sodium fluoride or silver fluoride. The solution may be water based solution. Methods of applying the medical device or solution are also disclosed.

Disclosed are compositions and formulations comprising enzymes or other biocatalyst that cleave surface-accessible DNA polymers and/or glycoprotein carbohydrate chains at galactose residues in dental calculus, and optionally further include one or more proteolytic enzymes, thereby destroying the structural integrity of the calculus, and allowing it to be readily removed without requiring special treatment by a trained dental professional. Also disclosed are methods for removing dental calculus using the disclosed compositions and formulations.

The present invention relates to a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of Units to 41 Units of modified BoNT/A per site and wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD.sub.50) in mice, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines; and up to three sites at the external part of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 574 Units, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 15 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: i. substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; ii. substitution of an acidic surface exposed amino acid residue with an uncharged amino acid residue; iii. substitution of an uncharged surface exposed amino acid residue with a basic amino acid residue; iv. insertion of a basic amino acid residue; and v. deletion of an acidic surface exposed amino acid residue. Also provided are corresponding methods of treatment and uses, as well as unit dosage forms, and kits.